[Hypoglycemia in patients treated with an external insulin pump]
Jean-Christophe Laurent1, Gerard Waeber, Juan Ruiz
1Service de médecine interne, CHUV, 1011 Lausanne. Jean-Christophe.Laurent@chuv.ch
Revue Medicale Suisse
|March 16, 2011
Summary
Continuous insulin infusion pumps improve glycemic control for diabetic patients but can cause hypoglycemia. Patients need education on managing pump adjustments during illness, exercise, or driving to prevent severe low blood sugar.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Management
Context:
- Insulin therapy is crucial for managing insulin-dependent diabetes.
- Continuous subcutaneous insulin infusion (CSII) therapy, or insulin pumps, offers improved glycemic control.
- Hypoglycemia remains a potential complication, especially during initial CSII use or in specific physiological states like pregnancy.
Purpose:
- To highlight the benefits and risks of insulin pump therapy in diabetes management.
- To emphasize the occurrence of hypoglycemia despite improved glycemic control with CSII.
- To outline management strategies for severe hypoglycemia and preventative measures for high-risk situations.
Summary:
- Insulin pumps can enhance glycemic control and reduce hypoglycemia frequency in insulin-dependent diabetics.
- Hypoglycemic episodes may still occur, particularly during early treatment, pregnancy, or due to specific triggers.
- Management involves stopping the pump, carbohydrate intake, and patient/caregiver education on adjusting insulin delivery for illness, exertion, and high-risk activities like driving.
Impact:
- Improved patient education and self-management for insulin pump users.
- Potential reduction in severe hypoglycemia events and associated complications.
- Enhanced safety for insulin pump users in daily life, including driving.
Related Concept Videos
01:15Hypoglycemia and Glucagon
747
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
747
01:16Insulin: Dosing Regimen and Adverse Effects
610
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
610
01:06Oral Hypoglycemic Agents: Glinides
531
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
531
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.0K
01:27Insulin Formulations: Types and Delivery
575
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
575
01:16Hormones Regulating Blood Glucose
6.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.2K